Pandemics and drug resistant bacteria afford opportunities for improved treatments for infectious diseases - namely the development of new prophylactic and therapeutic vaccines.
For pandemic readiness, there is a need for more effective, shelf-stable and easy to administer (no needles) vaccines for rapid deployment - especially in the developing world. Affordability is also a key requirement. This opens the door for new technology and new methods to improve vaccine production and delivery.
The incorporation of nano-emulsion-based vaccine adjuvants is one possibility to address stability and shelof life issues. Adjuvants have been unchanged in vaccine manufacture for a long time and this is now a budding area where new aduvants ae now being researched and tested in newer vaccines coming to the market -- particularly with some of the cancer therapeutic vaccines in development. But there is not reason to not extend improved adjuvants to other areas of vaccine development. GSK's HPV vaccine recently incorporated the first new adjuvant on the US market in more than 30 years and there is no reason for this type of innovation to be limited.
Posted by Bruce Lehr Jan 5th 2011.